4.7 Review

Regulation of efferocytosis as a novel cancer therapy

Journal

CELL COMMUNICATION AND SIGNALING
Volume 18, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12964-020-00542-9

Keywords

Efferocytosis; Tumor progression; Antitumor therapy; Immunosuppression; Phosphatidylserine; Phosphatidylserine receptor; CD47

Categories

Funding

  1. China Postdoctoral Science Foundation [2017 M612010]
  2. National Natural Science Foundation of China [81701144]

Ask authors/readers for more resources

Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect coordination among find-me, eat-me and don't-eat-me signals. These signaling pathways not only affect the proliferation, invasion, metastasis, and angiogenesis of tumor cells but also regulate adaptive responses and drug resistance to antitumor therapies. Therefore, efferocytosis-related molecules and pathways are potential targets for antitumor therapy. Besides, supplementing conventional chemotherapy, radiotherapy and other immunotherapies with efferocytosis-targeted therapy could enhance the therapeutic efficacy, reduce off-target toxicity, and promote patient outcome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available